Cargando…
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12‐175 [NCT01328626]; M13‐365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on venetoclax mono...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175959/ https://www.ncbi.nlm.nih.gov/pubmed/35845292 http://dx.doi.org/10.1002/jha2.177 |
_version_ | 1784722559737004032 |
---|---|
author | Handunnetti, Sasanka Anderson, Mary Ann Roberts, Andrew W. Davids, Matthew S. Ma, Shuo Boyer, Michelle Arzt, Jennifer Masud, Abdullah Al Popovic, Relja Jacobson, Amanda Kim, Su Y. Seymour, John F. |
author_facet | Handunnetti, Sasanka Anderson, Mary Ann Roberts, Andrew W. Davids, Matthew S. Ma, Shuo Boyer, Michelle Arzt, Jennifer Masud, Abdullah Al Popovic, Relja Jacobson, Amanda Kim, Su Y. Seymour, John F. |
author_sort | Handunnetti, Sasanka |
collection | PubMed |
description | Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12‐175 [NCT01328626]; M13‐365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on venetoclax monotherapy could receive added rituximab. Ten patients were evaluated (M12‐175, n = 8; M13‐365, n = 2), and five (50%) responded again upon addition of rituximab, including three complete and two partial responses. Responses were ongoing after 5–10 months of follow‐up. Addition of rituximab was well tolerated. These findings indicate potential clinical benefit with rituximab added to venetoclax post‐progression in some patients with R/R CLL. |
format | Online Article Text |
id | pubmed-9175959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91759592022-07-14 Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy Handunnetti, Sasanka Anderson, Mary Ann Roberts, Andrew W. Davids, Matthew S. Ma, Shuo Boyer, Michelle Arzt, Jennifer Masud, Abdullah Al Popovic, Relja Jacobson, Amanda Kim, Su Y. Seymour, John F. EJHaem Short Reports Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12‐175 [NCT01328626]; M13‐365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on venetoclax monotherapy could receive added rituximab. Ten patients were evaluated (M12‐175, n = 8; M13‐365, n = 2), and five (50%) responded again upon addition of rituximab, including three complete and two partial responses. Responses were ongoing after 5–10 months of follow‐up. Addition of rituximab was well tolerated. These findings indicate potential clinical benefit with rituximab added to venetoclax post‐progression in some patients with R/R CLL. John Wiley and Sons Inc. 2021-03-03 /pmc/articles/PMC9175959/ /pubmed/35845292 http://dx.doi.org/10.1002/jha2.177 Text en © 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Reports Handunnetti, Sasanka Anderson, Mary Ann Roberts, Andrew W. Davids, Matthew S. Ma, Shuo Boyer, Michelle Arzt, Jennifer Masud, Abdullah Al Popovic, Relja Jacobson, Amanda Kim, Su Y. Seymour, John F. Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy |
title | Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy |
title_full | Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy |
title_fullStr | Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy |
title_full_unstemmed | Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy |
title_short | Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy |
title_sort | addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy |
topic | Short Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175959/ https://www.ncbi.nlm.nih.gov/pubmed/35845292 http://dx.doi.org/10.1002/jha2.177 |
work_keys_str_mv | AT handunnettisasanka additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT andersonmaryann additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT robertsandreww additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT davidsmatthews additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT mashuo additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT boyermichelle additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT arztjennifer additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT masudabdullahal additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT popovicrelja additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT jacobsonamanda additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT kimsuy additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy AT seymourjohnf additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy |